AZN · story · 31 October
AstraZeneca · 3 headlines from 3 outlets, on 31 October 2026.
Executives discussed cancer vaccine development, a GLP-1 pill and the Oracle AI partnership.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
CNBC is the largest at 5.8, ahead of Fox Business (5.8). TradingView is the smallest at 1.7.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| CNBC | 5.8 |
| Fox Business | 5.8 |
| TradingView | 1.7 |
| Outlet | Headlines | Average tone |
|---|---|---|
| CNBC | 1 | +5.8 |
| Fox Business | 1 | +5.8 |
| TradingView | 1 | +1.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +5.8 | Obesity pill in development broadens future product range |
| +5.8 | Chief executive discusses vaccines and AI partnership |
| +1.7 | Cancer vaccine work to stay in-house for now |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.